Urška Janžič (Avtor), Urška Bidovec (Avtor), Katja Mohorčič (Avtor), Loredana Mrak (Avtor), Nina Fokter Dovnik (Avtor), Marija Ivanović (Avtor), Maja Ravnik (Avtor), Marina Čakš (Avtor), Erik Škof (Avtor), Jerneja Debeljak (Avtor), Peter Korošec (Avtor), Matija Rijavec (Avtor)

Povzetek

Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted.

Ključne besede

onkološko zdravljenje;imunogenost;osnovno cepljenje mRNA;čvrsti tumorji;anticancer treatment;immunogenicity;mRNA-based vaccination;solid cancer;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Založnik: Future Medicine
UDK: 616-006
COBISS: 111378179 Povezava se bo odprla v novem oknu
ISSN: 1479-6694
Št. ogledov: 141
Št. prenosov: 45
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Komentar vira: Soavtorji: Urška Bidovec-Stojković, Katja Mohorčič, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanović, Maja Ravnik, Marina Čaks, Erik Škof, Jerneja Debeljak, Peter Korošec & Matija Rijavec;
Strani: str. [1-10]
Letnik: ǂVol. ǂ
Zvezek: ǂiss. ǂ
Čas izdaje: 2022
DOI: 10.2217/fon-2022-0148
ID: 15730080